Peijia Medical-B (09996.HK) Surges Nearly 7% on NMPA Approval of TaurusTrio™ Transcatheter Aortic Valve System in China

According to the Zhitong Finance APP, Peijia Medical-B (09996) rose nearly 7%. As of the time of writing, it increased by 6.88%, trading at HK$6.21, with a turnover of HK$7.4878 million.

On the news front, Peijia Medical announced that on December 11, the company received approval from the National Medical Products Administration of the People's Republic of China for the registration application of the TaurusTrio™ Transcatheter Aortic Valve (TAV) System. The TaurusTrio™ TAV System was developed and manufactured by the company based on the exclusive license obtained from JenaValve Technology, Inc. (JenaValve) for the Trilogy™ Transcatheter Heart Valve (THV) System.

The announcement states that JenaValve's Trilogy™ THV system received CE Mark approval in May 2021, and as of the announcement date, has been used in over 1,000 commercial surgeries in real-world clinical practice. The company looks forward to the successful launch of the TaurusTrio™ TAV system in China, which is expected to provide Chinese patients suffering from severe AR with a safe and effective treatment option, thereby addressing a significant unmet clinical need.